Johnson & Johnson One-dose Vaccine 66% Successful
U.S. pharmaceutical and medical device maker Johnson & Johnson says after a global trial, the COVID-19 vaccine it has developed is 66% effective in preventing infection. The one-dose vaccine, which was developed by the company's Belgian subsidiary Janssen, appears to be 85% effective in preventing serious illness, even against the South African variant. Of the 44,000 people who participated in the trail in the U.S., South Africa and Brazil, no one who was given the vaccine died, the company said. "The potential to significantly reduce the burden of severe disease, by providing an effective and well-tolerated vaccine with just one immunization, is a critical component of the global public health response," Paul Stoffels, chief scientific officer of Johnson & Johnson, said in a company press release. "A one-shot vaccine is considered by the World…